Glaxo India Live Stock, Share, Price, Charts, Quotes, NSE, BSE
Incorporated in 1924 as H J Foster and Co, Glaxo India became a wholly-owned subsidiary of Joseph Nathan and Co., UK. Later in 1947, the company was renamed as Glaxo Laboratories (India). In 2000, Glaxo Wellcome plc and SmithKline plc merged under an agreement to form a new company, named GlaxoSmithKline plc. With this merger, Glaxo India is now an affiliate of GlaxoSmithKline plc, which holds 51 per cent of the equity. Its principal products are, Betamethasone based topical steroids, Betnovate-C, Betnovate-M, and Betnovate- GM. It also makes tablets from the same pharmaceutical ingredient, which is marketed under the brand name Betnesol. Its other key products are Cephalosporin, Ceftum, H2 blocker based on Ranitidine, Zinetac and the vitamin Celin. Glaxo manufactures the bulk drug from the basic stage, furfuryl alcohol, employing the technology developed by its parent, Glaxo Wellcome, UK.The company also markets over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks. Occupying a 6.5 per cent market share (2005), the company has Biddle Sawyer as its subsidiary. The company recently launched four new products licensed from companies in the US and Japan viz. Parit (Rabeprazole) in alliance with Eisai, Japan, Ferronine (a novel chelated iron) in alliance with Albion, USA and two new oral contraceptives in alliance with Organon. GSK plans to focus on the development of new technologies for Betamethasone, Clobetasone, Clobetasol and collaborative research work with GlaxoSmithKline - R&D, UK.
